Catalyst Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 7, 2024

CORAL GABLES, Fla., July 22, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,

GlobeNewswire7minutes ago

These Small-cap Stocks Score Highest When Screened for Quality

By Philip van Doorn An updated screen highlights smaller companies that have shown high long-term returns on invested capital and are expected to grow quickly over the next two years After years of

MarketWatchJul 17 11:57 ET

These Small-cap Stocks Score Highest When -2-

Source: FactSet Keep in

MarketWatchJul 17 11:57 ET

Insiders At Catalyst Pharmaceuticals Sold US$1.2m In Stock, Alluding To Potential Weakness

Over the past year, many Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) insiders sold a significant stake in the company which may have piqued investors' interest. Knowing whether insiders are

Simply Wall StJul 12 07:37 ET

BofA Securities Maintains Catalyst Pharmaceuticals(CPRX.US) With Buy Rating

BofA Securities analyst Jason Gerberry maintains $Catalyst Pharmaceuticals(CPRX.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 44.4% and a total average return

Moomoo NewsJul 10 09:31 ET · Ratings

Could The Market Be Wrong About Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Given Its Attractive Financial Prospects?

Catalyst Pharmaceuticals (NASDAQ:CPRX) has had a rough month with its share price down 8.7%. However, a closer look at its sound financials might cause you to think again. Given that fundamentals us

Simply Wall StJun 17 10:59 ET